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Abstract: In the absence of viremia, the diagnostics of Zika virus (ZIKV) infections must rely on
serological techniques. In order to improve the serological diagnosis of ZIKV, ZIKV-IgA and ZIKV-IgG
avidity assays were evaluated. Forty patients returning from ZIKV endemic areas, with confirmed or
suspected ZIKV infections were studied. Samples were classified as early acute, acute and late acute
according to the number of days post illness onset. Low avidity IgG was only detected at acute and
late acute stages and IgA mostly at the early acute and acute stages. The date of sampling provides
useful information and can help to choose the best technique to use at a determined moment in time
and to interpret low avidity IgG and IgA results, improving the serological diagnosis of ZIKV.
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1. Introduction
Zika virus (ZIKV), an emerging flavivirus transmitted mainly by mosquitos from the genus Aedes,
is a cause of public health concern. Prior to 2015, ZIKV outbreaks occurred in Africa, Southeast Asia,
and the Pacific Islands. In May 2015, the Pan American Health Organization issued an alert regarding
the first confirmed ZIKV infections in Brazil [1]. Between 2015 and 2016, large outbreaks occurred in
many countries in South and Central America as well as in the Caribbean [2]. Travelling for work or
tourism between Portugal and Spain and Latin America is very common. Portugal reported ZIKV
infections imported from Brazil for the first time in June 2015 [3]. In Spain, the first case of imported
ZIKV infection was confirmed in January 2016 [4]. Shortly after, in March 2016, vertical transmission
in an imported case was detected, in a 17-week pregnant woman [5].
ZIKV disease can be diagnosed within two weeks after onset of symptoms in serum or plasma,
and up to three weeks in urine by real-time PCR (RT-PCR) [6]. However, in the absence of detectable
ZIKV RNA or available molecular techniques, the only diagnostic methodology available is serology.
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The current knowledge on ZIKV antibody kinetics is still limited. In addition, the cross-reactivity
between ZIKV and other flaviviruses complicates serology. Thus, a positive result should always be
confirmed by neutralization tests (NT), and even this assay is not always able to provide a definitive
determination of the specific flavivirus causing the infection, particularly in individuals with a history
of flavivirus infection or vaccination [6,7].
The co-circulation of DENV and ZIKV in some regions and the possibility of reinfections by
the four DENV serotypes and/or ZIKV highlight the need for reliable serological tests when no
molecular tools are available, or when viremia drops to undetectable levels in the patients. One way of
discriminating infections between related viruses is to characterize IgG avidity [8]. Immunoglobulin
G avidity is low after primary antigenic challenge but increases throughout progressively during
subsequent weeks and months due to affinity maturation and antigen-driven B-cell selection. Avidity
assays have been used to differentiate between acute or primary infection and persistent infection,
recurrent infection, or reactivated disease in a number of infections and have been successfully used
for flaviviruses such as West Nile and dengue viruses [8–12]. On the other hand, the IgA response has
also been used as an indicator of recent and active infections in dengue and West Nile cases [13,14].
The objective of this study was to evaluate ZIKV IgG avidity and ZIKV IgA in their application of
diagnosis of ZIKV infections.
2. Materials and Methods
2.1. Studied Samples
A total of 79 serum samples, collected from 56 individuals were analyzed. These included 62
samples from 40 patients returning from ZIKV endemic areas in 2015–2016 and received for ZIKV
diagnostics at the National Health institutes in Portugal and Spain. As controls, 16 patients (17 samples)
with known recent or past DENV infection (15 collected in 2012, before the outbreak in the Americas,
and one in 2016), were studied. The study was approved by the Ethical Committee of the Institute of
Health Carlos III (code: CEI PI 70_2018).
These patients were organized in three groups: (I) 29 patients (43 samples) with ZIKV infection
(cases confirmed by positive RT-PCR in at least one of the available samples for each patient) (Table 1);
(II) 11 patients (19 samples) with serological suspicion of ZIKV infection (seroconversion and/or
positive IgG and IgM and negative RT PCR) (Table 2); (III and IV) the control group, including patients
with known recent (nine patients, 10 samples) or past (seven patients, seven samples) DENV infection
(Table 3).
Time elapsed after illness onset (days post symptom onset, dpso) was available for 60 samples
(39 patients) in groups I and II, allowing us to classify the samples according to their infectious stage
as early acute (≤5 dpso, n = 18), acute (6–20 dpso, n = 25) and late acute (>20 dpso, n = 17) [7,15].
2.2. Serological Diagnostic
IgM and IgG for DENV were determined using commercial ELISA (Panbio, Standard Diagnostics
Inc., Geonggi-do, South Korea) (Spanish samples) or by in-house immunofluorescence as previously
described [3] (Portuguese samples); IgM and IgG for ZIKV were determined using commercial ELISA
kits (Euroimmun, Lübeck, Germany). DENV IgM in ELISA was confirmed by a background assay as
described [10].
ZIKV-IgG avidity and ZIKV-IgA were tested by ELISA (Euroimmun, Lübeck, Germany) according
to the manufacturer’s instructions. Samples with ratio avidity index (RAI) lower than 40% were
regarded as having low avidity and those with RAI higher than 60% as having high avidity. Values
between 40% and 60% were considered equivocal. Serum dilutions started at 1:101. As advised,
when the OD was >1.2 without urea treatment and the RAI was >60%, we did fourfold dilutions,
until the OD was <1.2, to avoid false high avidity results, according to manufacturer´s instructions.
Whenever the OD reached a value of less than 0.140 without urea treatment after tentative dilutions,
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we considered as the final result the RAI’s of the last dilution with a valuable result. Results were
deemed as inconclusive when IgG dropped to a negative value after the next dilution. For the ZIKV
IgA assay samples were classified according to the ratio referred to a calibrator as positive (ratio was
>1.1), equivocal (0.8–1.1) or negative (<0.8). All ZIKV ELISA tests were based on the NS1 protein.
Neutralizing antibodies were detected by an in house neutralization test, using Vero E6 cells
and 100 TCID50% of ZIKV (strain MR-766). Samples were titrated in two-fold dilutions from 1/32.
neutralization titers <1/32 were considered indicative of the absence of ZIKV neutralizing antibodies.
Specificity and sensitivity were calculated for ZIKV-IgG avidity and ZIKV-IgA. These parameters
were also calculated for both techniques together, considering as positive the patients positive for
both approaches.
2.3. Molecular Diagnostics
RT PCR for ZIKV was performed with RealStar®Zika Virus (altona Diagnostics, Hamburg,
Germany) at Institute of Health Carlos III (Spain) or with the RT-PCR as previously described [16] at the
National Institute of Health Dr. Ricardo Jorge (Portugal). Positive results were confirmed in a second
amplification using the method described by Balm and co-workers with slight modifications [17].
The performance in both countries has been evaluated through external quality assays [18] showing
equivalent results.
3. Results
All patients in whom ZIKV infection was confirmed or suspected were infected in countries
from the Caribbean, South and Central America except for patient P4 who had sexually acquired the
infection (Tables 1 and 2).
In group I (Table 1), regarding dpso, from 29 RT PCR positive samples, 15 were classified as early
acute infections, 13 as acute and only one patient, a pregnant woman, presented a positive RT PCR
result in a late acute infection (32 dpso). IgM was present in 14 samples (from 13 patients), ranging
from 3–58 dpso (median 20), one at the early acute stage, six at acute stage and seven at the late acute
stage. IgG was detected in 23 samples from 21 patients, ranging from 3–261 dpso (median 11), four at
the early acute stage, 10 at the acute stage and nine at the late acute stage. Nine samples (from nine
patients) presented low avidity (7–58 dpso, median = 21), three at acute and six at the late acute stage.
Two patients presented high avidity results, at a late acute stage (36 and 261 dpso). IgA was present
in 19 samples from 17 patients, ranging from 3–27 dpso (median 10), three at the early acute stage,
13 at acute stage and three at late acute stage. In this group, five samples from five patients presented
DENV IgM positive results and 28 samples from 21 patients were positive for DENV IgG.
In group II (Table 2), there were 10 samples (from eight patients) with IgM positive results (9–45
dpso; median = 15). Eight of those samples were collected at acute stage, one at a late acute stage and
one was unknown. Regarding IgG, 14 samples (10 patients) were positive (10–76 dpso; median = 24.5),
six at acute stage, six at late acute stage and two unknown. Low avidity was observed in nine samples
(8 patients; 10–49 dpso; median = 17.5) five at the acute stage and three at the late acute stage. A high
avidity result was presented by a patient at 19 dpso (late acute stage). IgA was present in 11 samples
from nine patients (7–19 dpso; median = 13), one at the early acute stage and eight at the acute stage.
In Group II, three patients also showed DENV IgM and 15 samples (9 patients) presented DENV IgG.
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Table 1. Group I-PCR and serological results for patients with ZIKV infection.
Group ID/Sample Number Country of Infection DPSO PRNT (ZIKV) ZIKV RT-PCR ZIKV IgMRatio (ELISA)
ZIKV IgG
Ratio (ELISA)
ZIKV RAI
(Last Dilution)
IgA Ratio
(ELISA)
DENV
IgM *
DENV
IgG *
I P1/S1
Venezuela
32 ND Pos (u) Neg Neg Neg ND Neg
I P1/S2 58 ND ND Pos (2.0) Pos (3.9) L (35.9) Equiv (1.0) ND Pos
I P2/S1 Honduras 7 ND Pos (s) Neg Neg Neg Neg Neg
I P2/S2 21 Pos ND Pos (2.5) Pos (3.9) L (33.4) Neg ND Pos
I P3/S1 Dominican Republic 3 Pos Pos (u) Neg Neg Neg Neg Neg
I P3/S2 12 Pos Neg (s) Pos (3.5) Pos (1.3) L (18.2) Pos (2.6) Neg Neg
I P4/S1
Sexual transmission
0 ND Pos (u) Neg Neg Neg ND Pos
I P4/S2 12 ND Neg (s) Pos (1.4) Pos (2.9) L (15.6) Pos (5.3) ND Pos
I P5/S1
Brazil
0 ND Pos (u) Neg Neg Neg Neg Pos
I P5/S2 32 ND ND Pos (1.7) Pos (2.8) L (38.6) Neg ND Pos
I P6/S1
Unk
4 ND Pos (b,u) Neg Neg Neg Neg * Pos *
I P6/S2 26 ND ND Pos (1.2) Pos (3.2) L (38.8) Neg Neg * Pos *
I P7/S1
Brazil
4 ND Pos (b) Neg Neg Neg Neg * Pos *
I P7/S2 7 ND ND Neg Pos (6.9) Equiv (53.6) Pos (4.2) Neg * Pos *
I P8/S1 Honduras 4 ND Pos (u) Neg Pos (3.3) Equiv (40.6) Neg Neg Pos
I P9/S1 Honduras 3 Pos Pos (u) Neg Pos (6.4) Inc (72.6) Pos (2.7) ND Pos
I P10/S1 Venezuela 11 Pos Pos (u) Neg Pos (4.6) Equiv (41.3) Pos (2) Neg Pos
I P11/S1 Mexico 1 ND Pos (u) Neg Neg Neg ND Neg
I P12/S1 Colombia 7 Pos Pos (u) Pos (6.4) Pos (2.7) L (24.3) Pos (2.9) Neg Neg
I P13/S1 Colombia 3 ND Pos (u) Pos (2.4) Pos (2.2) Equiv (54.6) Pos (1.2) ND Pos
I P14/S1
Martinica
7 ND Pos (u) Neg Neg Neg Neg * Pos *
I P14/S2 21 ND ND Pos Equiv (1.0) Inc (71.3) Neg Neg * Pos *
I P15/S1 Brazil 12 ND Pos (u) Neg Pos (6.2) Inc (73.7) Pos (4.6) Neg * Pos *
I P16/S1 Brazil 20 ND Pos (u) Neg Pos (5.9) Inc (64.6) Pos (1.7) Neg * Pos *
I P17/S1 Brazil 3 ND Pos (u) Neg Neg Neg Neg * Neg *
I P18/S1 Brazil 5 ND Pos (b,u) Neg Neg Neg Neg * Neg *
I P19/S1 Unk 19 ND Pos (u) Pos (1.4) Neg Pos (1.2) Neg * Neg *
I P20/S1 Brazil 3 ND Pos (u) Neg Neg Neg Neg * Pos *
I P21/S1
Bolivia
6 ND Pos (u) Neg Pos (5.1) Equiv (51.0) Pos (4.7) Neg Pos
I P21/S2 27 Pos ND Neg Pos (5.7) Equiv (57.8) Pos (1.2) Neg Pos
I P22/S1 Dominican Republic 7 ND Pos (u) Neg Pos (7.1) Equiv (53.9) Pos (2.6) Neg Pos
I P22/S2 36 ND ND Neg Pos (6.2) H (80.4) Neg ND Pos
I P23/S1 unk 9 ND Pos (u) Neg Neg Neg Neg * Neg *
I P24/S1 unk 10 ND Pos (u) Neg Neg Neg Neg * Pos *
I P25/S1 Colombia <20 ND Pos (s) Neg Pos (2.8) Equiv (59) Pos (1.2) Pos Pos
I P26/S1 Venezuela 4 ND Pos (u) Neg Pos (5.0) Equiv (43.5) Pos (3.4) Pos Pos
I P27/S1 Brazil 3 ND Pos (u) Neg Neg Neg Neg * Neg *
I P27/S2
Brazil
9 ND ND Pos (4.6) Neg Pos (2.6) Pos * Neg *
I P27/S3 261 ND ND Neg Pos (1.4) H (72.8) Neg Neg * Pos *
I P28/S1
Brazil
5 ND Pos (u) Neg Neg Neg Neg * Neg *
I P28/S2 21 ND ND Pos (3.5) Pos (1.7) L (29.4) Pos (4.4) Pos * Pos *
I P29/S1
Colombia
6 ND Pos (u) Pos (2.6) Equiv (1.0) Equiv (54.8) Pos (4.8) Neg * Pos *
I P29/S2 24 ND ND Pos (2.0) Pos (1.5) L (33.4) Pos (4.3) Pos * Pos *
DPSO—Days post illness onset; Equiv—Equivocal; Inc—inconclusive; L—low avidity; ND—not determined; Neg—negative result; Pos—positive result; PRNT—plaque reduction
neutralization test; RAI—Relative avidity index; unk—unknown; (b)—blood sample; (s)—serum sample; (u)—urine sample. DENV IgM and IgG: the samples marked * were tested by IIF,
the remaining by ELISA.
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Table 2. Group II. Patients with serological suspicion of ZIKV infection.
Group ID/SampleNumber
Country of
Infection DPSO
PRNT
(ZIKV)
ZIKV
RT-PCR
ZIKV IgM
Ratio (ELISA)
ZIKV IgG
Ratio (ELISA)
ZIKV RAI
(Last Dilution)
IgA Ratio
(ELISA)
DENV
IgM *
DENV
IgG *
II P30/S1 Dominican Republic 4 ND ND Neg Neg Neg Neg Neg
II P30/S2 32 ND ND Neg Pos (2.9) L (30.4) Neg Neg Neg
II P31/S1 Brazil ≤7 ND ND Equiv (1.1) Neg Pos (1.2) Neg Pos
II P31/S2 ≤18 Pos ND Pos (4.6) Pos (3.1) L (16.1) Pos (5.1) ND Pos
II P32/S1 Venezuela 2 ND ND Neg Neg Neg Neg Pos
II P32/S2 19 Pos ND Pos (1.3) Pos (6.1) H (65.8) Pos (5.0) Neg Pos
II P33/S1 Unk 9 ND Neg (b) Pos (2.57) Neg Pos (4.1) Neg * Neg *
II P33/S2 30 ND ND Equiv (1.0) Pos (2.9) L (32.4) Neg Neg * Neg *
II P34/S1 Venezuela 49 Pos ND Neg Pos (2.9) L (30.2) Neg Pos Pos
II P34/S2 76 Pos ND Neg Pos (3.6) Equiv (44.9) Neg Neg Pos
II P35/S1 Colombia unk Pos Neg (s) Pos (7.4) Pos (3.7) L (23.4) Pos (4.1) Pos Pos
II P36/S1 Brazil 10 ND Neg (b,u) Pos (2.5) Pos (1.4) L (31.6) Pos (5.2) Pos Pos
II P37/S1 Brazil 13 ND Neg (b) Pos (4.2) Neg Pos (1.3) Neg * Pos *
II P38/S1 Brazil 13 ND Neg (b) Pos (2.8) Pos (1.9) L (18.2) Pos (5.1) Neg * Pos *
II P38/S2 15 ND ND Pos (1.6) Pos (3.0) L (29.4) Pos (2.47) Neg * Pos *
II P39/S1 Dominican Republic 17 ND Neg (s) Pos (2.4) Pos (3.8) L (38.1) Pos (4.55) ND Pos *
II P39/S2 45 Pos Neg Pos (2.5) Pos (2.8) Equiv (45.5) Equiv (0.97) ND Pos
II P40/S1 Dominican Republic unk ND ND Equiv (1.0) Pos (6.4) Inc (72.5) Pos (1.96) ND Pos
II P40/S2 67¨ ND Neg (s) Neg Pos (6.1) H (68.6) Neg ND Pos
DPSO—Days post illness onset; Equiv—Equivocal; Inc—inconclusive; L—low avidity; ND—not determined; Neg—negative result; Pos—positive result; PRNT—plaque reduction
neutralization test; RAI—Relative avidity index; unk—unknown. (b)—blood sample; (s)—serum sample; (u)—urine sample. DENV IgM and IgG: the samples marked * were tested by IIF,
the remaining by ELISA.
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In group III (Table 3), three patients showed ZIKV low avidity IgG (P44/S1, P45/S1 and P52/S1,
and three were equivocal (P42/S1, P53/S1 and P56/S1). In relation to ZIKV IgA, only one sample
(P56/S1) showed an equivocal result. All the other samples were negative for IgA.
Figure 1A,B summarize the serological results for samples from groups I and II for low avidity
IgG and IgA, respectively, related to the ZIKV infectious stages.
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Figure 1. Serol i l t sting in patients from groups I and II. (A) ZIKV IgG avidity results; (B) ZIKV
IgA Results.
In their application to identify ZIKV recent infection cases, the avidity IgG testing showed a
sensitivity value of 42.5% (17/40), (95% confidence interval [CI]: 28.5–57.8), being the specificity 62.5
(10/16) (95%CI: 38.6–81.5). Regarding ZIKV-IgA, sensitivity was 65% (26/40) (95%CI: 49.5–77.9)
and specificity as 93.8% (15/16) (95%CI: 71.7–98.9). For both approaches simultane sly,
the corresponding figures were 25% (10/40) (95% CI 14.2–40.2) and 100% (16/16) (CI95%: 80.6–100).
4. Discussion
All patients with suspected or confirmed ZIKV infection had traveled to countries with
co-circulation of ZIKV and DENV. In our study five ZIKV PCR positive p tients also presented
with D -IgM positive results and/or low avidity and/or IgA positive results for ZIKV. Similar
results were also obtained in Group II, with three patients presenting s rolo ical positive samples
for both viruses. Steinhagen et al. [7], using the sa e assay we used here (NS1-based ELISA’s),
found no cross-reactivity between ZIKV and DENV IgM. As such, our results can lead us to the
suspicion of co-infection or, at least, shortly followed sequential infections with both viruses. Two
cases of co-infection have already been reported in Pernambuco, Brazil, during a DENV outbreak
in 2016 [19]. Other two in New Caledonia, 2014, one of those being autochthonous and the other
a patient returning from the French Polynesia [20]. However, cross reactivity between ZIKV and
DENV is well known [21,22]. In one study, sera from both DENV-naive and DENV pre-immune ZIKV
patients strongly bound to ZIKV as well as DENV, with cross-reactive antibodies targeting both E and
NS1 proteins. The four patient samples in that study were from primary ZIKV cases, where infection
occurred during travel to ZIKV-afflicted areas [21]. Moreover, Lanciotti and colleagues [23] suggested
that if ZIKV is causing secondary infections in a population with DENV (or other flaviviruses)
background immunity, extensive cross-reactivity in the dengue IgM assay can occur. In this way,
ultimate confirmation of co-infection would only rely on PCR positive results for both viruses.
Unfortunately, by the time of this study, there was no sample available to perform DENV PCR.
All these facts reinforce the need for serological tools to understand the time of infection in the
absence of active viremia. This discrimination is very important due to the clinical role of ZIKV
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infections in pregnancy, which can result in fetal malformations, or in men that can transmit the virus
sexually [24,25].
Overall, we had positive ZIKV-IgM results from day three to day 45. A recent similar study
reported positive ZIKV-IgM results as early as day two and until 42 dpso [26]. Then again, Kadkhoda
et al., using the same assay were able to detect positive IgM only at five dpso, testing a limited number
of samples (n = 13) [27]. In the present study, ZIKV IgM was not detected in 13 out of 29 PCR positive
patients. For seven of those 14 patients, the antibodies probably had not yet reached detectable levels,
since samples were collected at the early acute stage (≤5 dpso), as previously reported [7] but we
also cannot also exclude that the sensitivity of the technique may play its role in the results. Also,
intrinsic immune factors cannot be discarded and might account for differences between individuals
or populations, as reported by Lustig and colleagues who observed that ZIKV-IgM kinetics differed in
Israeli, European and Chilean travelers [26]. Alternatively, the absence of IgM anti-ZIKV at acute stages
concomitantly with high IgG ratio in some patients, may indicate a secondary infection. According to
our cases, an IgG ratio > 2.0 was often associated with equivocal or inconclusive avidity IgG results
and accompanied by a negative ZIKV-IgM result. Similar results were reported for DENV, where in
secondary infections, the IgM response was variable or absent, accompanied by a dramatic increase in
IgG antibodies [7,28]. Analogous kinetics has also been observed for ZIKV primary and secondary
infections during the ZIKV epidemic in Micronesia in 2007 [23]. All these results strongly suggest than
previous flavivirus infection could have an important impact on the interpretation of ZIKV avidity
assay. According to the manufacturer of the kit, false high avidity values may be recorded due to high
levels of antibodies, which may have been the case of patient P32, Table 2, whose follow up sample
was taken 19 dpso. In contrast, the high avidity result for sample P27/S3, (Table 1), was expected since
it represented a follow up sample taken nine months after onset of symptoms.
In relation to IgA testing, positive results were obtained in nine samples (eight patients) from
ZIKV infections, negative for IgM, two of them at the early acute stage, suggesting that IgA is detectable
before IgM. Interestingly, Balmaseda and colleagues suggested that detection of IgA is more sensitive
than IgM [29]. The majority of our ZIKV IgA positive results were obtained in samples collected at
the early acute and acute stages and only three at the late acute stage (S21/S2, 27 dpso, P28/S2, 21
dpso and P29/S2, 24 dpso, Table 1). Individual kinetics may be observed but, in general, IgA seems
to be of rapid appearance and short duration. As an example, in patient P33 with available paired
samples (Table 2), there was a positive IgA result on day nine which turned negative on day 30. These
results are in accordance with previous studies for other flaviviruses [13,14,27]. These facts can indicate
that ZIKV IgA might support recent ZIKV infection, thereby adding a tool for acute ZIKV infection
diagnostics with acceptable specificity and high sensitivity, as suggested by Zhang and colleagues [30].
Nearly all the patients in Group II showed some indicators of recent ZIKV infection even though
samples had not been tested or were PCR-negative (Table 2). Thus, all the patients in this group could
be considered infected by ZIKV.
In groups III and IV (recent and past DENV infections) three patients showed ZIKV low avidity
IgG (samples P44/S1, P45/S1 and P52/S1, Table 3). One of them, P44, worked on a cruise ship and was
exposed to DENV, acquiring the infection during the outbreak occurred in Madeira Island [31]; this
patient could have travelled to various countries and been exposed to other flaviviruses, namely by
vaccination for Yellow Fever, Japanese Encephalitis or Tick-Borne Encephalitis viruses. For the other
two patients there was no available information and thus we cannot totally exclude the possibility of a
ZIKV infection in none of them, in despite of the year in which the samples were taken (before the
Zika outbreak in the Americas). The three low and three equivocal ZIKA avidity results from Table 3,
that are from patients assumed to have solely a dengue or other flavivirus infection, illustrates the
on-going cross-reactivity within the flavivirus group. No positive results were obtained using the IgA
assay (only a sample showed an equivocal one), thus ensuring the specificity of this approach.
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Table 3. PCR and serological results for patients with recent DENV infections (Group III) and with past DENV infections (Group IV).
Group ID/SampleNumber DPSO
Country of
Infection
PRNT
(ZIKV)
ZIKV
RT-PCR
ZIKV IgM
Ratio (ELISA)
ZIKV IgG
Ratio (ELISA)
ZIKV RAI (Last
Dilution) (ELISA)
IgA Ratio
(ELISA)
DENV IgM
(ELISA)
DENV IgG
(ELISA)
III P41/S1 Unk Unk ND ND Neg Neg Neg Pos Neg
III P42/S1 Unk Unk ND ND Neg Pos (1.5) Equiv (45.2) Neg Pos Pos
III P43/S1 Unk Cambodia ND ND Neg Neg Neg Pos Pos
III P44/S1 Unk Cruise with a stop atMadeira Island ND ND Neg Pos (2.9) L (27.4) Neg Pos Pos
III P45/S1 Unk Americas ND ND Neg Pos (1.3) L (10.4) Neg Pos Pos
III P46/S1 Unk Unk ND ND Neg Neg Neg Pos Pos
III P47/S1 Unk Dominican Republic ND ND Neg Neg Neg Pos Pos
III P48/S1 Unk Unk ND ND Neg Neg Neg Pos Pos
III P49/S1 8 Unk ND ND Neg Neg Neg ND Pos
III P49/S2 13 Unk ND ND Neg Neg Neg Pos Pos
IV P50/S1 Unk Cambodia ND ND Neg Equiv (0.9) Neg Neg Pos
IV P51/S1 Unk Unk ND ND Neg Neg Neg Neg Pos
IV P52/S1 Unk Unk ND ND Neg Pos (1.5) L (39.4) Neg Neg Pos
IV P53/S1 Unk Unk ND ND Neg Pos (1.2) Equiv (41.8) Neg Neg Pos
IV P54/S1 Unk Venezuela ND ND Neg Neg Neg Neg Pos
IV P55/S1 Unk Unk ND ND Neg Neg Neg Neg Pos
IV P56/S1 Unk Unk ND ND Neg Pos (1.4) Equiv (41.2) Equiv (0.96) Neg Pos
DPSO—Days post illness onset; Equiv—Equivocal; Inc—inconclusive; L—low avidity; ND—not determined; Neg—negative result; Pos—positive result; PRNT—plaque reduction
neutralization test; RAI—Relative avidity index; unk—unknown.
Viruses 2019, 11, 179 9 of 11
The main limitation of this paper was the selection of samples, especially the controls. Control
cases were retrospectively selected as having a recent or past DENV infection, prior to the ZIKV
epidemics in the Americas. This selection was based on the fact that both viruses share epidemiological
and clinical issues, and a high degree of cross reactivity. Furthermore, the selection of the controls did
not consider the time elapsed after the onset, making difficult the comparison of cases and controls.
The selection of samples has, as well, impact on the sensitivity and specificity of the assays in evaluation,
being especially important for the calculation of specificity.
5. Conclusions
Simultaneous ZIKV IgM, low avidity IgG and IgA positive results seem to corroborate a recent
ZIKV infection. However, the serological diagnosis of ZIKV in symptomatic patients should be
supported by careful inquiry at the time of admission. The date of symptom onset together with
the date of sample collection thus provides useful information and may help interpret ZIKV low
avidity IgG and IgA. In the early acute and acute stages of the infection, IgA tests seem to be more
valuable, while low avidity IgG appears to be more useful at the acute and late acute stages. Lastly,
the combined use of both techniques seems preferable in order to avoid false positive results. Further
studies, with a larger number of patients, with follow up samples, would be necessary to clarify the
kinetics of ZIKV antibodies, and the maturation of IgG avidity.
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